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Although uremia is well known as the most common cause of
pruritus, the mechanisms of pruritus in chronic hemodialysis
patients remain unclear. The purpose was to characterize
uremic pruritus in more detail and to investigate whether
severe pruritus is a marker for poor prognosis. A total of 1773
adult hemodialysis patients were studied. A questionnaire
was given to each patient to assess the intensity and
frequency, as well as pruritus-related sleep disturbance. We
analyzed the relationship between clinical and laboratory
data and the severity of pruritus in hemodialysis patients and
followed them for 24 months prospectively. In total, 453
patients had severe pruritus with a visual analogue scale
(VAS) score more than or equal to 7.0. Among them, more
than 70% complained of sleep disturbance, whereas the
majority of patients with a VAS score of less than 7.0 had no
sleep disturbance. Male gender, high levels of blood urea
nitrogen, b2-microglobulin (b2MG), hypercalcemia, and
hyperphosphatemia were identified as independent risk
factors for the development of severe pruritus, whereas a low
level of calcium and intact-parathyroid hormone were
associated with reduced risk. During the follow-up, 171
(9.64%) patients died. The prognosis of patients with severe
pruritus was significantly worse than the others. Moreover,
severe pruritus was independently associated with death
even after adjusting for other clinical factors including
diabetes mellitus, age, b2MG, and albumin. Severe uremic
pruritus caused by multiple factors, not only affects the
quality of life but may also be associated with poor outcome
in chronic hemodialysis patients.
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Pruritus has been well recognized as a common and
sometimes unbearable complication in patients with chronic
renal failure.1–3 Although the association between chronic
renal failure and skin itching has been recognized for more
than a century, the molecular basis of pruritus in chronic
renal failure remains an elusive problem, mainly because of
its subjective and capricious nature and the strong influence
of psychological factors.
There is no confirmed evidence that uremic pruritus can
be caused by a single factor,4,5 whereas many metabolic
factors have been implicated in the pathogenesis of itching,
for example, hypercalcemia, hyperphosphatemia, secondary
hyperparathyroidism, and hypermagnesemia.6,7 It has been
reported that higher dialysis efficacy with a good nutritional
state reduces the prevalence and degree of pruritus in
hemodialyzed patients.8 In addition to affecting the quality
of life and sleep, uremic pruritus has been reported to be a
marker of poor outcome in patients on long-term hemodia-
lysis.9 However, the prognostic significance of uremic
pruritus has not been examined in Japanese patients. Because
many of the previous clinical studies on uremic pruritus have
been performed on a small number of patients and the
involvement of multiple confounding factors has not been
fully evaluated, the impact of uremic pruritus on survival of
hemodialysis patients is yet to be confirmed.
To clarify the risk factors for the development of severe
uremic pruritus, we investigated the relationship between
clinical and laboratory data and the development of severe
uremic pruritus in a large number of patients undergoing
chronic hemodialysis. This study also investigated the
prognostic significance of uremic pruritus for survival of
Japanese patients undergoing chronic hemodialysis treatment
by prospective observation for 24 months.
RESULTS
In total, 1773 patients were included in the analyses. Figure 1
shows the distribution of patients with each range of visual
analogue scale (VAS) scores, subjectively assessed for skin
itching of the patients. In all, 1292 (72.9%) of the 1773 had
VAS score of at least more than 1.0. The patients were
stratified into three groups as described in the Patients and
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Methods. The validity of this simple stratification method
was evaluated by subsequent analyses and by survival
analysis. Table 1 shows the distribution of the categorized
frequencies of skin itching, sleep disturbances due to itching,
as well as antipruritic treatments used in each group
of patients. It was obvious that the intensity of the itching
was strongly associated with the frequency (w2¼ 266.669,
Po0.0001). In patients with severe pruritus, about 80%
complained of itching at least more than a few times a day
(grade 4 or 5), and more than 70% of them complained of
sleep disturbance, ranging from grade 2 to 4, whereas the
majority of patients in the other groups had no sleep
disturbance (w2¼ 254.974, Po0.0001). The frequencies of
any kind of antipruritic treatment in each group were also
strongly correlated with the stratified intensity of pruritus.
The mean values of grades of frequency and sleep disturbance
were also compared using the Kruskal–Wallis H statistic
among the three groups. Both frequency (Figure 2a) and
sleep disturbance (Figure 2b) were significantly different
across groups (a, Po0.0001; b, Po0.0001), clearly indicating
that the increased intensity of pruritus is associated with the
frequency of skin scratching episodes and sleep disturbance,
leading to a decline in the quality of life.
Table 2 shows the demographic and laboratory data of
the study subjects and comparisons among groups with
each grade of uremic pruritus intensity at the study entry.
The group with severe pruritus had a significantly higher
proportion of male gender, longer duration of dialysis, as well
as higher levels of serum creatinine, blood urea nitrogen
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Figure 1 | Number of patients in each range of VAS scores for
intensity of uremic pruritus.
Table 1 | Frequencies of skin itching, sleep disturbances due to itching, and anti-pruritic treatment in each group of patients
Pruritus grade
All patients Mild (VASo4.0)
Moderate (VAS
4.0–6.9)
Severe
(VAS47.0)
Among three
groups
Between severe
vs others
N=1773 N=826 N=494 N=453 P-value v2 P-value v2
Frequency
Less than once a week 63 (5.54) 28 (12.50) 23 (4.79) 12 (2.77)
Less than once every few
days
235 (20.67) 93 (41.52) 100 (20.83) 42 (9.70)
More than once a day 230 (20.23) 59 (26.34) 132 (27.50) 39 (9.01)
More than a few times a
day
419 (36.85) 36 (16.07) 175 (36.46) 208 (48.04)
Total restlessness 190 (16.71) 8 (3.57) 50 (10.42) 132 (30.48) o0.0001 266.669 o0.0001 198.247
Number of answers 1137 (100) 224 (100) 480 (100) 433 (100)
Sleep disturbance
No sleep disturbance 592 (51.57) 186 (79.49) 284 (59.17) 122 (28.11)
Waking up less than a few
times a night
322 (28.05) 45 (19.23) 143 (29.79) 134 (30.88)
Waking up more than a
few times a night
156 (13.59) 3 (1.28) 43 (8.96) 110 (25.34)
Sleeplessness 78 (6.79) 0 (0.00) 10 (2.08) 68 (15.67) o0.0001 254.974 o0.0001 225.626
Number of answers 1148 (100) 234 (100) 480 (100) 434 (100)
Anti-pruritic treatment
Antipruritic lotions 718 (40.50) 106 (12.83) 285 (57.69) 327 (72.19) o0.0001 511.722 o0.0001 244.788
Antihistamines 220 (12.41) 24 (2.91) 67 (13.56) 129 (28.48) o0.0001 176.849 o0.0001 139.913
Sedatives 75 (4.23) 3 (0.36) 26 (5.23) 46 (10.12) o0.0001 71.036 o0.0001 52.474
Ultraviolet therapy 4 (0.23) 0 (0.00) 1 (0.20) 3 (0.66) 0.0574 5.716 0.0235 5.135
VAS, visual analogue scale; (), %.
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Figure 2 | The (mean7s.d.) values of grades of frequency and
sleep disturbance were compared using the Kruskal–Wallis H
statistic among the three groups. Both grades for (a) frequency of
skin scratching episode and (b) sleep disturbance due to skin itching
were significantly different across groups (a, Po0.0001; b, Po0.0001).
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(BUN), b2-microglobulin (b2MG), intact-parathyroid
hormone (i-PTH), calcium, phosphate, and serum C-reactive
protein levels (CRP than the other groups, while there was no
significant difference among the three groups for age, body
mass index, incidence of diabetes mellitus, hematocrit,
history of parathyroidectomy, total protein, albumin, Kt/V,
and blood pressure. The frequency of erythropoietin users in
the group with mild pruritus was significantly higher than
that of the other groups (P¼ 0.0105), whereas the weekly
dose of erythropoietin was not significantly different among
the three groups, as was the type of dialysis membrane (data
not shown).
The multiple logistic regression analysis was used to test
the significance of confounding factors for the development
of severe uremic pruritus. As shown in Table 3, the final
logistic regression model showed increased odds ratio for
males of 1.514 (95% confidence interval (CI), 1.175–1.950;
P¼ 0.0013), BUN (X81.3 mg/dl) of 1.422 (95% CI,
1.028–1.967; P¼ 0.0036), b2MG (X34.1 mg/dl) of 1.647
(95% CI, 1.198–2.264; P¼ 0.0021), calcium (X9.5 mg/dl) of
1.431 (95% CI, 1.053–1.945; P¼ 0.0220), and phosphate
(X6.6 mg/dl) of 1.650 (95% CI, 1.200–2.269; P¼ 0.0021). On
the other hand, low levels of calcium (p8.1 mg/dl) and
i-PTH (p200 pg/ml) were associated with reduced risk for
severe pruritus (odds ratio for low calcium¼ 0.639; 95% CI,
0.457–0.893; P¼ 0.0087; odds ratio for low i-PTH¼ 0.565;
95% CI, 0.414–0.772; P¼ 0.0003, respectively). Age, diabetes
mellitus, duration of dialysis, level of creatine, hematocrit,
Table 2 | Demographics and laboratory data of the study population and comparisons among groups with each grade of
uremic pruritus
Pruritus grade
All patients Mild Moderate Severe
Among three groups Between Severe vs Others
N=1773 N=826 N=494 N=453 P-value v2 P-value v2
Gender (male %) 58.9 52.8 62.3 66.4 o0.0001 25.849 0.0001 14.489
Age (year) 60.2712.8 60.5713.3 60.1712.5 59.8712.3 0.4411 0.2345
BMI (kg/m2) 21.1872.79 20.9472.63 21.3272.77 21.5173.09 0.0916 0.0654
Duration of dialysis (months) 123.6790.1 118.8788.7 122.7792.1 133.0790.0 0.0048 0.0014
Diabetes mellitus (%) 18.9 19.7 19.2 16.8 0.4052 1.807 0.1312 2.278
History of parathyroidectomy 72 32 23 17 0.7344 0.633 0.7020 0.146
Serum creatinine (mg/dl) 11.072.6 10.772.7 11.272.4 11.472.7 0.0001 0.0010
BUN (mg/dl) 70.7716.1 69.3716.2 71.6715.7 72.3716.3 0.0008 0.0060
Hematocrit (%) 30.374.4 30.274.3 30.574.4 30.374.6 0.7378 0.9039
Total protein (g/dl) 6.470.6 6.470.7 6.470.6 6.470.6 0.5627 0.5486
Albumin (g/dl) 4.0170.52 4.0170.57 3.9970.47 4.0170.49 0.3302 0.6948
b2-microglobulin (mg/dl) 29.378.7 28.678.7 29.077.8 30.779.3 0.0018 0.0006
Kt/V
a 1.2170.26 1.2370.28 1.2070.27 1.1970.22 0.0957 0.1180
CRPa (mg/dl) 0.6571.4 0.6571.34 0.5771.12 0.7571.75 0.0517 0.0180
Intact-PTH (pg/ml) 209.47228.3 192.27215.7 203.67226.9 246.57247.8 o0.0001 o0.0001
Calcium (mg/dl) 8.7371.35 8.5571.43 8.8671.24 8.9471.28 0.0001 0.0005
Phosphate (mg/dl) 5.6271.47 5.4171.40 5.7171.44 5.9171.58 0.0001 o0.0001
EPO users (%) 74.1 79.3 69.4 68.2 0.0378 6.552 0.1346 2.238
EPO dose (U/week) 4278 3151 4506 3018 3954 3147 4153 3423 0.2973 0.7133
Blood pressure (mm Hg)
Systolic 151.0725.4 150.7726.0 151.3724.3 151.4725.5 0.7235 0.5147
Diastolic 83.1740.1 83.1740.4 81.5723.0 84.7752.3 0.8598 0.6391
Values are mean7s.d.
VAS, visual analogue scale; BUN, blood urea nitrogen; PTH, parathyroid hormone; BMI, body mass index; CRP, C-reactive protein; EPO, erythropoietin.
aData of Kt/V and CRP are for 547 and 331 patients, respectively.
Table 3 | Multiple logistic regression analysis for severe
uremic pruritus (VASX7.0)
Variables v2 P-value Odds ratio 95% CI
Gender
Female Referent
Male 10.300 0.0013 1.514 1.175, 1.950
BUN (mg/dl)
p60.0 1.553 0.2126 1.237 0.885, 1.728
460.0, o81.2 Referent
X81.3 4.513 0.0036 1.422 1.028, 1.967
b2MG (mg/dl)
o23.6 0.048 0.8263 0.965 0.701, 1.329
23.6, o34.1 Referent
X34.1 9.456 0.0021 1.647 1.198, 2.264
Intact-PTH (pg/ml)
o200 12.899 0.0003 0.565 0.414, 0.772
X200, o400 Referent
X400 0.178 0.6732 0.916 0.608, 1.379
Calcium (mg/dl)
p8.1 6.893 0.0087 0.639 0.457, 0.893
48.1, o9.5 Referent
X9.5 5.242 0.0220 1.431 1.053, 1.945
Phosphate (mg/dl)
p4.6 0.068 0.7945 0.956 0.685, 1.335
44.7, o6.6 Referent
X6.6 9.486 0.0021 1.650 1.200, 2.269
VAS, visual analogue scale; BUN, blood urea nitrogen; PTH, parathyroid hormone;
b2MG, b2-microglobulin.
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albumin, Kt/V, and blood pressure were not recognized as
independent risk factors for severe uremic pruritus in this
model.
Next, to investigate whether severe uremic pruritus has an
impact on death, the patients were prospectively followed up
until death or for 24 months. During the follow-up, 171 of
the 1773 patients (9.64%) died. The causes of death are listed
in Table 4. There was no significant difference in the cause
of death among each group (w2¼ 7.283, P¼ 0.7100). Death
due to infection tended to be more prevalent in patients
with severe uremic pruritus compared with other groups,
although the difference was not significant.
Figure 3 shows the survival of patients analyzed by the
Kaplan–Meier method. The prognosis of patients with severe
pruritus was significantly worse than the others (log rank test,
w2¼ 14.426; P¼ 0.0001). To investigate further the signifi-
cance of severe uremic pruritus as an independent predictive
marker for death, the multivariate Cox proportional hazard
regression model was used. After forcing severe pruritus
(VASX7.0) in the model, significant variables, other than
CRP because of incomplete data, were selected using a
stepwise backward procedure so that the maximum like-
lihood ratio was generated (w2¼ 134.988; Po0.0001). This
model revealed that severe uremic pruritus was an indepen-
dent predictive factor for death even after adjusting for other
clinical risk factors (Table 5, Hazard ratio (HR) for severe
pruritus¼ 1.595; 95% CI, 1.160–2.381; P¼ 0.0084). In this
model, diabetes mellitus, age, and low level of albumin were
independent risk factors for death, whereas low b2MG was
protective. In the 331 patients in whom CRP values were
available, survival rates analyzed by the Kaplan–Meier
method was lower in patients with CRP levels above
the 75 percentile (40.51 mg/dl) (log rank test, w2¼ 18.602;
Po0.0001).
DISCUSSION
Uremic pruritus remains a frequent and tormenting problem
in patients with end-stage renal disease, mainly because of the
lack of knowledge of the underlying pathophysiological
mechanisms. In the present study, a large number of adult
patients undergoing chronic hemodialysis treatment, at least
for more than 24 months, were analyzed in order to clarify
the risk factors for the development of severe uremic
pruritus. To our knowledge, this is the largest study
population used to characterize the multiple confounding
factors for severe uremic pruritus. We stratified patients into
three groups according to the intensity of their skin itching,
which was subjectively estimated by VAS scores. The scoring
method for the intensity of pruritus employed in the present
study was simple compared to the detailed scoring system of
previous studies.10,11 However, the validity of the stratifica-
tion in this study was confirmed by the subsequent analyses,
which tested the relationship between the intensity and the
frequency of skin scratching episodes, its influence on sleep
disturbance, as well as its relationship to the necessity of
treatments, indicating that the stratified intensity of pruritus
is significantly associated with a fall in the quality of life.
Since pruritus is affected by seasonal changes, we conducted
the study in a spring season, which corresponds to the
average temperature and humidity in Niigata prefecture.
The result of the logistic regression analysis revealed
that the development of severe uremic pruritus is associated
with multiple clinical factors. Male gender, high pre-dialysis
level of BUN, high levels of b2MG, calcium, and phosphate,
as well as i-PTH were independently associated with the
development of severe uremic pruritus. All these factors
have already been reported in previous studies,1,4,6,8,12,13
although their relative impacts have not been fully tested by
Table 4 | Causes of death in each group
Pruritus grade
Cause of death Over all Mild Moderate Severe
Cardiac 51 (29.8) 22 (30.6) 16 (42.1) 13 (21.3)
Infection 28 (16.4) 9 (12.5) 5 (13.2) 14 (23.0)
Cerebrovascular 27 (15.8) 13 (18.1) 5 (13.2) 9 (14.8)
Withdrawal 13 (7.6) 5 (6.9) 3 (7.9) 5 (8.2)
Sudden death 6 (3.5) 3 (4.2) 1 (2.6) 2 (3.3)
Others 46 (26.9) 20 (27.8) 8 (21.1) 18 (29.5)
Total death 171 72 38 61
(), %; the total percentage may not be 100% because of rounding.
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Figure 3 | Kaplan–Meier analysis for the survival of patients. The
prognosis of patients with severe uremic pruritus was significantly
worse than those of the others (log rank test, w2¼ 14.426; P¼ 0.0001).
Table 5 | Cox proportional hazard model to test the signifi-
cance of clinical covariates and uremic pruritus as predictors
of death
Variable P-value HR 95% CI
Severe pruritus
VAS47.0 0.0084 1.595 1.160, 2.381
Diabetes mellitus 0.0047 1.711 1.179, 2.485
Age (years) o0.0001 1.053 1.037, 1.069
b2MG (mg/dl)
p23.6 0.0287 0.588 0.365, 0.946
423.6, o34.1 Referent
X34.1 0.4468 1.163 0.788, 1.714
Alb (g/dl)
p3.7 0.0003 2.097 1.400, 3.141
43.7, o4.4 Referent
X4.4 0.0340 0.552 0.318, 0.956
HR, Hazard ratio; CI, confidence interval; MG, microglobulin; Alb, albumin.
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multivariate analysis in a large population. The duration of
dialysis was longer in the patients with severe pruritus when
simply compared, but it was not selected as an independent
factor in the multivariate logistic regression model. This may
be because the longer duration of dialysis was correlated with
other significant risk factors such as the high levels of BUN,
b2MG, and i-PTH. In fact, significant correlations were
observed between dialysis duration and these factors in our
patients (data not shown).
The mean level of BUN was significantly higher in patients
with severe pruritus when simply compared with those of
other groups, and the multiple logistic regression analysis
indicated that a high level of BUN was a significant risk
factor for severe uremic pruritus. This may indicate that
a substantial proportion of patients with severe uremic
pruritus are in an underdialysis state, although Kt/V was no
different among groups, when simply compared. Kt/V does
not quantify the removal of mid- and large-sized molecules
which may be responsible for uremic pruritus.14 There is also
a possibility that severe uremic pruritus is associated with
a hypercatabolic state; however, we could not analyze the
relation between protein catabolic rate and pruritus because
we lacked the data of interdialytic urinary urea nitrogen
excretion in patients with urine output. Nonetheless, the
significantly higher CRP levels in patients with severe
pruritus support the latest possibility. To establish a definitive
link between a high level of BUN and uremic pruritus,
further investigations with precise assessments of the
nutritional state of every patient, using other markers such
as subjective global nutritional assessment (SGNA), measur-
ing several anthropometric markers, plasma insulin, insulin
growth factor-1, are needed.15
In addition to hyperparathyroidism, divalent-ion abnorm-
alities, and a high level of BUN, the data indicated that a high
level of b2MG is independently associated with the develop-
ment of severe uremic pruritus. While it has been revealed
that the b2MG content in skin tissue increases with the
duration of dialysis,16 there is no evidence for a direct
cause-and-effect relationship between b2MG and pruritus.
Although it has been established that b2MG is a major
component of dialysis-associated amyloidosis,17 it is not
likely that uremic pruritus is directly caused by amyloidosis,
because the incidence of accumulation of b2MG amyloid
fibrils in tissues other than joints and juxta-articular
structures is extremely low.18 If anything, there is a possibility
that increased accumulation of middle-molecular weight
molecules, which are unknown so far and reflected by the
high level of B2MG, is a pruritogenic factor in hemodialysis
patients. Recently, two new hypotheses for the underlying
pathophysiological mechanisms of uremic pruritus have been
proposed, the immuno-hypothesis and opioid hypothesis.19
Mettang et al. have suggested that numerous factors
including IL-2, TNF-a, and CD4 cells are probably involved
in the pathogenesis of uremic pruritus. Therefore, the
increased level of b2MG in patients with severe uremic
pruritus may indicate that a condition which promotes the
production or accumulation of IL-2 or TNF-a and activation
of CD4 cells also promotes the development of pruritus.
The important and interesting finding of the present study
is that the prognosis of patients with severe uremic pruritus
was significantly poorer than that of other groups, and that
the impact of uremic pruritus was independent even after
adjusting for other significant clinical risk factors for death.
The mechanism by which severe uremic pruritus had a
significant impact on survival is unknown. It may be related
to a chronic subclinical inflammation as suggested by the
significantly higher CRP levels in patients with severe
pruritus. In our study, patients with higher CRP had a lower
survival rate. Unfortunately, we could not conduct further
analysis to prove this relation because CRP was not routinely
measured in all of our patients. Chronic inflammation has
been increasingly recognized as a poor survival factor in
chronic hemodialysis patients.15,20,21 The causes of death in
patients with severe uremic pruritus were no different from
those in other patient groups. The mortality rate of about
10% during 2-year observation in this study was compatible
with other reports in Japanese hemodialysis patients. We
could not accurately measure drug dosage or continuous
duration of medical therapies such as ACE inhibitors, active
Vitamin D, phosphate binders, or HMG-CoA reductase
inhibitors during the clinical course in this study. The
presence of uremic neuropathy, and whether it has any
relation with the severity of pruritus and poor outcome, was
also not checked in our study. It has been suggested that
somatic and autonomic dysfunction may be related to uremic
pruritus.22 Further investigation with a longer duration of
observation and fixed medical protocol is necessary to clarify
the mechanism by which severe uremic pruritus was
accompanied with poor outcome.
In conclusion, this is the largest population-based study
with quantitative analysis of uremic pruritus in chronic
hemodialysis patients. Our study indicated that severe uremic
pruritus is an independent predictor of poor outcome, and
that the etiology of uremic pruritus is multiple. Therefore, we
recommend individualized treatment to prevent the deve-
lopment of severe pruritus, which may consequently improve
the outcome of patients undergoing chronic hemodialysis
therapy.
MATERIALS AND METHODS
Study subjects
In the year 2000, a total of 3840 adult patients underwent chronic
hemodialysis treatment at 41 institutions in Niigata Prefecture,
Japan. Among them, 1773 patients, who did consent to participate
in this study, were recruited from March to May 2000, while patients
with a history of pruritus or dermatologic disease antedating renal
failure were excluded. Also, patients with systemic diseases such
as malignancy, cholestatic liver disease, and those with psychiatric
disorders or non-compliance to hemodialysis treatment were
excluded. The patient’s mean age was 60.2712.8 years (range;
20–92) and mean duration of hemodialysis was 123.6790.1 months
(range; 24–408). The underlying renal diseases were chronic
glomerulonephritis (N¼ 1052), diabetic nephropathy (N¼ 332),
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polycystic kidney disease (N¼ 73), nephrosclerosis (N¼ 95),
chronic pyelonephritis (N¼ 30), other diseases (N¼ 172), and
unknown (N¼ 19). All patients gave written informed consent
before enrollment in the study.
Estimation of pruritus, analysis of clinical data, and follow-up
At the study entry, a questionnaire was given to each patient to
assess the intensity and frequency of pruritus, as well as its influence
on the quality of sleep. Each patient estimated his or her current skin
itching intensity using a VAS (0¼ no pruritus to 10¼ unbearable
pruritus). Frequency of itching was categorized into five grades as
follows: 1, scratching episodes less than once a week; 2, more than
once a week but less than once a day; 3, more than once a day; 4,
more than a few times a day; 5, total restlessness. Sleep disturbance
was categorized as follows: 1, no sleep disturbance (no episodes of
waking up because of itching); 2, waking up, but less than a few
times a night, due to skin itching; 3, waking up more than a few
times a night; 4, sleeplessness due to skin itching.
Clinical characteristics including age, sex, body weight, height,
blood pressure, duration of dialysis (in months), type of dialysis
membrane, prior history of parathyroidectomy, erythropoietin and
antipruritic treatments at the time of study entry were recorded.
Laboratory data including levels of serum creatinine (mg/dl), BUN
(mg/dl), albumin (g/dl), hematocrit (%), b2MG (mg/l), i-PTH (pg/
ml), calcium (mg/dl), and phosphate (mg/dl) before the dialysis
session were measured. Dialysis adequacy expressed as Kt/V values,
estimated by the method described by Daugirdas,23 and CRP levels
(mg/dl) were only available in 547 and 331 patients, respectively.
In all institutions, hemodialysis was conducted using high-flux
dialysis membranes, such as polymethylmethacrylate, poly-acrylo-
nitrile, polysulfone, and triacetate with bicarbonate as a dialysis
buffer. Water purified by reverse osmosis was used as the dialysate in
all patients.
To test the significance of severe pruritus as a predictive
risk factor for death, all patients were prospectively followed up
until death, or May 1, 2002. Causes of death were classified as
cerebrovascular, infection, cardiac, dialysis withdrawal, sudden
death, and others. Dialysis withdrawal-associated deaths were noted
in patients who were unable to undergo regular dialysis because of
severe malnutrition or unstable hemodynamic condition.
Statistical analysis
Statview 5.0 statistical software (Abacus Concepts, Inc. Berkeley, CA,
USA) was used for the analyses on a Macintosh G4 computer. The
w2 analysis was used when comparing categorical variables between
the groups. Continuous variables were compared using the
Mann–Whitney U-test or Kruskal–Wallis analysis of variance. All
tests were two-sided. A P-value less than 0.05 was considered
significant. The patients were stratified into three groups according
to the itching intensity as follows: group 1, patients with no or mild
pruritus, whose VAS scores were less than 4.0 (N¼ 826); group 2,
those with moderate pruritus, whose VAS were 4.0–6.9 (N¼ 494);
and group 3, those with severe pruritus, whose VAS were equal or
more than 7.0 (N¼ 453). Odds ratio with 95% CI for the
development of severe pruritus (VAS score X7.0) in association
with potential confounding variables (sex, age, the duration of
dialysis, and the presence or absence of diabetes mellitus) were
calculated on the basis of univariate and multiple logistic-regression
analysis. In this analysis, the levels of serum creatinine, BUN,
hematocrit, calcium, phosphate, and CRP were stratified into three
groups by interquartile range, so that patients were stratified into
lower than 25 percentile, 25–75 percentile, or higher than 75
percentile groups. All possible predictor variables were used in a
logistic regression model with severe pruritus as the dependent
variable. Then, the model was simplified in a stepwise fashion by
removing variables which had a P-value of greater than 0.05.
The Kaplan–Meier method and the Cox proportional hazard
regression model were used to test the impact of severe pruritus on
the survival of patients. In the Cox proportional model, significant
variables were selected using a stepwise backward procedure after
forcing severe pruritus (VASX7.0) in the model so that the
maximum likelihood ratio was generated.
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